← Back to Clinical Trials
Recruiting Phase 2 NCT06031428

NCT06031428 MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly Incarcerated Black Men

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06031428
Status Recruiting
Phase Phase 2
Sponsor Medical College of Wisconsin
Condition Diabetes Mellitus, Type 2
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2024-02-20
Primary Completion 2027-06-01

Eligibility & Interventions

Sex Male only
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
MANAGe-DM - novel nurse case managementMonthly Educational Mailing

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.

This trial targets 100 participants in total. It began in 2024-02-20 with a primary completion date of 2027-06-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The study is a randomized control trial involving 100 participants (formerly incarcerated Black men with poorly controlled diabetes) to examine the effect of a tailored nurse case manager on glycemic control and other clinical outcomes, self-care behaviors, and quality of life at 6 months post-randomization.

Eligibility Criteria

Inclusion Criteria: * age ≥18 years * identify as Black or African American * identify as male * formerly incarcerated in a state or federal prison system or county jail * clinical diagnosis of type 2 diabetes with HbA1c ≥8% at the screening visit * able to communicate in English. Exclusion Criteria: * mental confusion on screening interview suggesting significant dementia * current participation in other diabetes clinical trials * active psychosis or acute mental disorder * life expectancy \<12 months * awaiting arraignment, trial, sentencing in the criminal legal system * on active surveillance by the criminal legal system, meaning on house arrest or subject to electronic monitoring

Contact & Investigator

Central Contact

Laura Hawks, MD

✉ lhawks@mcw.edu

📞 414-955-8020

Principal Investigator

Laura Hawks, MD

PRINCIPAL INVESTIGATOR

Medical College of Wisconsin

Frequently Asked Questions

Who can join the NCT06031428 clinical trial?

This trial is open to male participants only, aged 18 Years or older, studying Diabetes Mellitus, Type 2. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT06031428 trial and what does that mean for participants?

Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.

Is NCT06031428 currently recruiting?

Yes, NCT06031428 is actively recruiting participants. Contact the research team at lhawks@mcw.edu for enrollment information.

Where is the NCT06031428 trial being conducted?

This trial is being conducted at Milwaukee, United States.

Who is sponsoring the NCT06031428 clinical trial?

NCT06031428 is sponsored by Medical College of Wisconsin. The principal investigator is Laura Hawks, MD at Medical College of Wisconsin. The trial plans to enroll 100 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology